On January 2, 2025, Cencora acquired an 85% interest in Retina Consultants of America (RCA) for $4,036.1 million in cash, plus $694.4 million of contingent consideration related to equity units for certain RCA physicians and members of management that retained the remaining 15% interest in RCA, $556.0 million for the settlement of a receivable resulting from a pre-existing commercial relationship between the company and RCA, and $393.1 million for contingent consideration payable to the sellers associated with RCA's achievement of certain predefined business objectives.

1. 01

   On January 2, 2025, Cencora acquired an 85% interest in Retina Consultants of America (RCA) for $4,036.1 million in cash, plus $694.4 million of contingent consideration related to equity units for certain RCA physicians and members of management that retained the remaining 15% interest in RCA, $556.0 million for the settlement of a receivable resulting from a pre-existing commercial relationship between the company and RCA, and $393.1 million for contingent consideration payable to the sellers associated with RCA's achievement of certain predefined business objectives.

2. 02

   Cencora said revenue increased by $7.0 billion (10.3%) from the prior year quarter and $16.3 billion (11.6%) for the 6 months ended, primarily due to growth in the U.S. Healthcare Solutions segment. The company added that sales of GLP-1 products in that segment increased by $2.2 billion (36.1%) from the prior year quarter.

3. 03

   Cencora said gross profit increased by $521.8 million (20.6%) from the prior year quarter and $611.0 million (12.2%) for the 6 months ended. The company said gains from antitrust litigation settlements were $198.6 million in the quarter, compared to $8.7 million in the prior year quarter, and that LIFO expense in the current year periods offset part of the increase in comparison to LIFO credits in the prior year periods.

4. 04

   Cencora said it generated $632.5 million of cash from operating activities during the 6 months ended March 31, 2025, compared to $6.7 million in the prior year period, and that it raised $1.8 billion of senior notes and $1.5 billion of variable-rate term loan to finance a portion of the RCA acquisition.

Key figures

Quarter ended March 31, 2025

Revenue

$75.5B

Operating income

$1.0B

Net income

$718M

EPS

$3.68

Gross profit

$3.1B

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.